KCM
LXRX icon

Kornitzer Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Kornitzer Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-766,495
Closed -$9.42M – 480
2017
Q3 		$9.42M Buy
+766,495
New +$11.3M 0.16% 181

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Kornitzer Capital Management's LXRX Position: Q4 2017 in Review

Kornitzer Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 766,495 shares — an estimated $9.42M sold.

Kornitzer Capital Management first reported a position in LXRX in Q3 2017 and held it in 1 quarter. The position peaked at $9.42M in Q3 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Kornitzer Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Kornitzer Capital Management sold 766,495 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $9.42M.
  • Kornitzer Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Kornitzer Capital Management's Lexicon Pharmaceuticals position peaked at $9.42M in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Kornitzer Capital Management's 13F filing for Q4 2017, filed 31 Jan 2018.